January 31, 2015 7:38 PM ET

Pharmaceuticals

Company Overview of Presidio Pharmaceuticals, Inc.

Company Overview

Presidio Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the discovery and development of small-molecule antiviral therapeutics. The company primarily focuses on developing therapies for hepatitis C virus (HCV) infection. Its portfolio includes PPI-668, a pan-genotypic HCV NS5A inhibitor; and PPI-383, a pan-genotypic non-nucleoside NS5B inhibitor. The company was founded in 2006 and is based in San Francisco, California.

1700 Owens Street

Suite 585

San Francisco, CA 94158

United States

Founded in 2006

Phone:

415-655-7560

Fax:

415-986-2864

Key Executives for Presidio Pharmaceuticals, Inc.

Acting President
Co-Founder and Director
Chief Medical Advisor
Age: 66
Vice President of Chemistry
Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2014.

Presidio Pharmaceuticals, Inc. Key Developments

Ascletis and Presidio Enter into an Exclusive Licensing Agreement

Ascletis and Presidio announced that they have entered into an exclusive licensing agreement for Presidio's clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16. The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China. Presidio will retain all rights in the rest of the world. This licensing agreement for PPI-668 adds a fourth drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China. PPI-668 is a pan-genotypic HCV NS5A inhibitor that has shown high SVR rates in combination with other DAAs in a phase 2 study. Under the terms of the agreement, Ascletis will fund clinical development, manufacturing and commercialization of PPI-668 in greater China and Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Greater China.

Pharco Pharmaceuticals Licenses Clinical Stage Hepatitis C Virus (HCV) NS5A Inhibitor PPI-668 from Presidio Pharmaceuticals

Pharco Pharmaceuticals and Presidio Pharmaceuticals announced that they have entered into an exclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection in Egypt. This exclusive license includes an opportunity for Pharco to expand its licensed territory to one or more additional countries in the MENA region. Pharco will fund clinical development and commercialization of PPI-668 in Egypt, and potentially the MENA region. Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Egypt and potentially the MENA region. Pharco made an equity investment in Presidio related to the license agreement.

Presidio Pharmaceuticals, Inc. Announces Non-Exclusive Collaboration with Boehringer Ingelheim for Phase IIa Clinical Trial of an Interferon-Free, All-Oral, Direct-Acting Antiviral Combination Treatment for Patients with Chronic Hepatitis C Virus Infection

Presidio Pharmaceuticals, Inc. announced a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa clinical trial of an interferon-free, all-oral, direct-acting antiviral (DAA) combination treatment for patients with chronic hepatitis C virus (HCV) infection. The collaborative trial will evaluate Presidio's pan-genotypic HCV NS5A inhibitor (PPI-668) in combination with Boehringer Ingelheim's HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. Both companies have agreed to initiate the Phase II, 12-week treatment study in the second quarter of 2013. The trial will measure on-treatment antiviral responses and sustained virologic response rates (SVR) to the triple DAA combination regimen, with or without ribavirin. Presidio Pharmaceuticals will have primary operational responsibility for the trial, in close collaboration with Boehringer Ingelheim. Sustained virologic response results at 4- and 12-weeks post-treatment are expected to be available in the fourth quarter of 2013. Both companies continue to retain all rights to their respective compounds during this collaboration.

Similar Private Companies By Industry

Company Name Region
Semafore Pharmaceuticals, Inc. United States
Equi-Tox, Inc. United States
Smith-Collins Pharmaceutical, Inc. United States
Krenitsky Pharmaceuticals Inc. United States
Prasco, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Presidio Pharmaceuticals, Inc., please visit www.presidiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.